This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Cadence Pharmaceuticals Inc. Q2 2010 Earnings Call Transcript

Cadence Pharmaceuticals Inc. (CADX)

Q2 2010 Earnings Call

August 05, 2010


Ted Schroeder - President and CEO

Jim Breitmeyer - EVP and Chief Medical Officer

Bill LaRue - EVP and CFO


Charles Duncan - JMP Securities

Eric Schmidt - Cowen and Company

Adam Cutler - Canaccord

Greg Fraser - Banc of America-Merrill Lynch

John Newman - Oppenheimer



Welcome to the Cadence Pharmaceuticals Second Quarter 2010 Financial Results Conference Call. On the call today are Ted Schroeder, President and CEO, Jim Breitmeyer, Executive Vice President and Chief Medical Officer, and Bill LaRue, Senior Vice President and Chief Financial Officer.

At this time, I would like to inform you that this conference is being recorded and that all participants are in a listen-only mode. (Operator Instruction)

Our first is speaker is Bill LaRue. Go ahead, sir.

Bill LaRue

Before we get started today, I would like to remind you that statements included in this conference call that are not a description of historical facts are forward-looking statements. Such forward-looking statements include statements regarding: the timeframe in which the FDA is expected to complete its review of our NDA for OFIRMEV, and our belief that our NDA will be sufficient for the FDA to approve this product candidate; our readiness to launch OFIRMEV, and the potential strength of any such launch; the sufficiency of the our capital resources to fund our operations through the approval of initial launch period of OFIRMEV; our ability to complete future drawdowns under our loan facility; the potential for us acquire Incline Therapeutics and the anticipated strategic benefit of any such acquisition, and all of our financial estimates and projections.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
CADX $0.00 0.00%
AAPL $92.70 -0.58%
FB $118.03 0.19%
GOOG $705.04 0.51%
TSLA $210.48 -0.50%


Chart of I:DJI
DOW 17,590.58 -70.13 -0.40%
S&P 500 2,042.16 -8.47 -0.41%
NASDAQ 4,689.8610 -27.2330 -0.58%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs